{"entity":{"id":"radar-hodgkin","kind":"trial","name":"RADAR","aka":["RADAR trial","A2VD in early-stage Hodgkin lymphoma","ISRCTN RADAR"],"tldr":"An international trial asking whether swapping one old chemotherapy drug for a targeted antibody lets most people with early Hodgkin lymphoma avoid radiotherapy altogether.","summary":"RADAR is two parallel trials sharing one analysis: trial 1 led by University College London across Europe, Australia and New Zealand, trial 2 led by the Canadian Cancer Trials Group across North America, with the datasets combined to reach the target of 1,042 participants.\n\nParticipants are randomised to ABVD (doxorubicin, bleomycin, vinblastine and dacarbazine) or A2VD, which replaces the bleomycin with brentuximab vedotin and adds growth factor support. Everyone has a centrally reviewed scan after two cycles. A Deauville score of 1 to 3 means one further cycle of the randomised chemotherapy and then follow-up with no radiotherapy at all. A Deauville score of 4 means two further cycles followed by involved-site radiotherapy. A Deauville score of 5 means coming off trial treatment. Follow-up runs for a minimum of five years, and primary completion is estimated for September 2030.\n\nThe design is a direct response to HD16 and EORTC H10, which both showed that an interim scan alone is not enough to justify dropping radiotherapy. RADAR changes the chemotherapy as well, on the hypothesis that a more active regimen will make the omission safe. The primary endpoint is progression-free survival. Sites are open in Australia, Belgium, Canada, Denmark, Ireland, the Netherlands, New Zealand, Portugal, Slovakia, Spain, the United Kingdom and the United States.","status":"active","asOf":"2026-10-01","links":[{"label":"ClinicalTrials.gov NCT04685616","url":"https://clinicaltrials.gov/study/NCT04685616"}],"tags":["lymphoma-evidence"],"related":[],"cancers":["early-stage-classical-hodgkin-lymphoma","hodgkin-lymphoma"],"sections":["adcs","radiation","imaging"],"technologies":["adc","pet-ct","radiotherapy"],"targets":["cd30"],"drugs":["brentuximab-vedotin","doxorubicin","bleomycin","vinblastine","dacarbazine"],"companies":[],"institutions":["cruk"],"pathways":[],"terms":["deauville-score","abvd-beacopp"],"trials":["hd16","eortc-h10","echelon-1"],"people":[],"bottlenecks":["b-survivorship","b-toxicity-qol"],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT04685616","phase":"3","setting":"Untreated early-stage classical Hodgkin lymphoma: ABVD against A2VD, which replaces the bleomycin with brentuximab vedotin, with treatment after two cycles set by a centrally reviewed scan","sponsor":"University College London with the Canadian Cancer Trials Group","started":"2022-04-14","startedType":"actual","enrolled":1042,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/radar-hodgkin/","neighbours":{"cancer":[{"id":"early-stage-classical-hodgkin-lymphoma","kind":"cancer","name":"Early-stage classical Hodgkin lymphoma (stage I to II)","route":"/cancers/early-stage-classical-hodgkin-lymphoma/"},{"id":"hodgkin-lymphoma","kind":"cancer","name":"Hodgkin lymphoma","route":"/cancers/hodgkin-lymphoma/"},{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}],"section":[{"id":"adcs","kind":"section","name":"Antibody-Drug Conjugates","route":"/fronts/adcs/"},{"id":"imaging","kind":"section","name":"Imaging","route":"/fronts/imaging/"},{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/"}],"term":[{"id":"abvd-beacopp","kind":"term","name":"ABVD, BEACOPP and BrECADD (Hodgkin lymphoma regimens)","route":"/terms/abvd-beacopp/"},{"id":"deauville-score","kind":"term","name":"Deauville five-point scale","route":"/terms/deauville-score/"},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/"}],"target":[{"id":"cd30","kind":"target","name":"CD30","route":"/targets/cd30/"}],"drug":[{"id":"bleomycin","kind":"drug","name":"Bleomycin","route":"/drugs/bleomycin/"},{"id":"brentuximab-vedotin","kind":"drug","name":"Brentuximab vedotin","route":"/drugs/brentuximab-vedotin/"},{"id":"dacarbazine","kind":"drug","name":"Dacarbazine","route":"/drugs/dacarbazine/"},{"id":"doxorubicin","kind":"drug","name":"Doxorubicin","route":"/drugs/doxorubicin/"},{"id":"vinblastine","kind":"drug","name":"Vinblastine","route":"/drugs/vinblastine/"}],"institution":[{"id":"cruk","kind":"institution","name":"Cancer Research UK","route":"/institutions/cruk/"}],"trial":[{"id":"echelon-1","kind":"trial","name":"ECHELON-1","route":"/trials/echelon-1/"},{"id":"eortc-h10","kind":"trial","name":"EORTC/LYSA/FIL H10","route":"/trials/eortc-h10/"},{"id":"hd16","kind":"trial","name":"GHSG HD16","route":"/trials/hd16/"}],"bottleneck":[{"id":"b-survivorship","kind":"bottleneck","name":"Survivorship and late effects are neglected","route":"/bottlenecks/b-survivorship/"},{"id":"b-toxicity-qol","kind":"bottleneck","name":"Toxicity and quality of life are undervalued","route":"/bottlenecks/b-toxicity-qol/"}],"paper":[{"id":"paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015","kind":"paper","name":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk","route":"/key-papers/paper-van-nimwegen-cardiovascular-disease-after-hodgkin-jama-intern-med-2015/"},{"id":"paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017","kind":"paper","name":"Early positron emission tomography response-adapted treatment in stage I and II Hodgkin lymphoma: final results of the randomized EORTC/LYSA/FIL H10 trial","route":"/key-papers/paper-eortc-h10-pet-adapted-early-hodgkin-jco-2017/"},{"id":"paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019","kind":"paper","name":"Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group","route":"/key-papers/paper-ghsg-hd16-pet-guided-early-favourable-hodgkin-jco-2019/"},{"id":"paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015","kind":"paper","name":"Second cancer risk up to 40 years after treatment for Hodgkin's lymphoma","route":"/key-papers/paper-schaapveld-second-cancer-risk-40-years-hodgkin-nejm-2015/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}],"idea":[{"id":"lymphoma-ev-radiotherapy-free-early-hodgkin","kind":"idea","name":"A radiotherapy-free cure for early Hodgkin lymphoma that actually holds","route":"/ideas/lymphoma-ev-radiotherapy-free-early-hodgkin/"}]}}